title: Immunotherapy: first do no harm.
abstract: Immunotherapy continues to be a treatment modality that is used most exclusively by allergists. The acceptance of immunotherapy for treating children with allergic rhinitis or asthma has been limited by the lack of adequate numbers of pediatric double-blind, placebo-controlled trials of specific allergen immunotherapy; use of venom immunotherapy is more clearly supported by current data. Children represent a unique group of patients where allergic disease may not only be treated using immunotherapy resulting in reduction of symptoms, signs, and complications of disease, but may also hold the best potential for the evasive goal of prevention of the development of future allergic disease.
authors.affiliation: Department of Medicine, Section of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin Medical School, K4/934 CSC #9988, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, USA. mhm@medicine.wisc.edu
authors.forename: Mark H
authors.initials: MH
authors.lastname: Moss
mesh_terms: D000485:Allergens / Q000276:immunology / Q000627:therapeutic use; D001249:Asthma / Q000628:therapy*; D002648:Child; D000075202:Contraindications; D004306:Dose-Response Relationship, Immunologic; D004632:Emergency Medical Services; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D018579:Patient Selection; D006255:Rhinitis, Allergic, Seasonal / Q000628:therapy*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000485:Allergens